natgillin/translations-raw huggingface dataset:
The process according to claim 14, wherein 2-5 equivalents of NaO(t-Bu), 2-5 equivalents piperazine, 0.2-0.6 mole-% Pddba2, and 0.6-1 mole-% rac-BINAP are dispersed in toluene to obtain mixture A', to which mixture approximately 1 equivalent 2-bromo-iodobezene is added to obtain mixture B', to which mixture 1 equivalent 2,4-dimenthylthiophenol is added and the resulting mixture is heated to reflux for 3-7 hours to obtain 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. 
Postupak prema zahtjevu 14, gdje se 2-5 ekvivalenata NaO(t-Bu), 2-5 ekvivalenata piperazina, 0.2-0.6 mol% Pddba2 i 0.6-1 mol-% rac-BINAP dispergiraju u toluenu da se dobije smjesa A’, u tu smjesu se dodaje oko 1 ekvivalent 2-bromo-jodobenzola da se dobije smesa B’, u tu smjesu se dodaje 1 ekvivalent 2,4-dimetiltiofenola i finalna se smjesa zagrijava do refluksa 3-7 sati da se dobije 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazin.
A compound as claimed in any of claims 1-20 for use in the treatment of psychosis or a psychotic condition, or for treatment of substance abuse. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1-20, naznačen time što je namijenjen upotrebi liječenju psihoze ili psihotičnog stanja, ili liječenju zloupotrebe tvari.
A pharmaceutical composition for use in the treatment of depression, alcohol addiction and/or dependence, premenstrual tension, premenstrual syndrome or premenstrual dysphoric disorder, comprising 3a-hydroxy-3β-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one or a pharmaceutically-acceptable salt or solvate thereof, and one or more pharmaceutically-acceptable excipients, wherein the composition provides steady state plasma levels of 3a-hydroxy-3β-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 5 ng/mL to 500 ng/mL for a duration of from 12 h to 24 h following administration. 
Farmaceutski sastav, naznačen time da sadrži 3a-hidroksi-3β-metoksimetil-21-(1’-imidazolil)-5a-pregnan-20-on ili njegovu farmaceutski prihvatljivu sol ili solvat i jedan ili više farmaceutski prihvatljivih ekscipijenata za upotrebu u liječenju opsesivno- kompulzivnog poremećaja, posttraumatskog stresnog poremećaja ili socijalnog anksioznog poremećaja u ljudskom subjektu, pri čemu sastav daje stacionarno stanje razina u plazmi 3a-hidroksi-3β-metoksimetil-21-(1’-imidazolil)-5a-pregnan-20-ona u rasponu od 5 ng/ml do 500 ng/ml u trajanju od 6 sati do 24 sata nakon davanja.
The pharmaceutical composition for use according to claim 1, wherein the composition provides steady state plasma levels of 3a-hydroxy-3β-methoxymethyl-2,1-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 50 ng/mL to 250 ng/mL. 
Farmaceutski sastav za upotrebu prema patentnom zahtjevu 1 ili 2, naznačen time da daje stacionarno stanje razine u plazmi 3a-hidroksi-3β-metoksimetil-21-(1’-imidazolil)-5a-pregnan-20-ona u rasponu od 50 ng/ml to 250 ng/ml.
The pharmaceutical composition for use according to any one of claims 1 to 4, wherein the pharmaceutical composition comprises from 20 mg to 40 mg, preferably 30 mg, 3a-hydroxy-3β-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one. 
Farmaceutski sastav za upotrebu prema bilo kojem patentnom zahtjevu od 1 do 4, naznačen time da farmaceutski sastav sadrži od 20 mg do 40 mg, poželjno 30 mg, 3a-hidroksi-3β-metoksimetil-21-(1’-imidazolil)-5a-pregnan-20-ona.
The pharmaceutical composition for use according to any one of claims 1 to 5, wherein the pharmaceutical composition is suitable for oral administration. 
Farmaceutski sastav za upotrebu prema bilo kojem patentnom zahtjevu od 1 do 5, naznačen time da je farmaceutski sastav prikladan za oralno davanje.
wherein R1, R2, G and p are as defined for formula (I) and X is a leaving group, with a compound of formula (V): wherein R3 and R4 are as defined in claim 1. 
[image] gdje su R1, R2, G i p definirani kao u patentnom zahtjevu 1, a X je izlazna skupina, sa spojem formule (V): [image] gdje su R3 i R4 definirani kao u patentnom zahtjevu 1.
Use of a compound as claimed in any of claims 1-20 in the manufacture of a medicament for the treatment of psychosis or a psychotic condition, or is substance abuse. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1-20, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje psihoze ili psihotičnog stanja, ili zloupotrebe tvari.
A compound of formula (1): or a tautomer, stereoisomer, N-oxide, or a pharmacologically acceptable salt, hydrate or solvate of any of the foregoing, wherein: 
Spoj, naznačen time, da ima formulu (1): [image] ili tautomer, stereoizomer, N-oksid, ili farmakološki prihvatljiv(a) sol, hidrat ili solvat od bilo kojeg od gore navedenih, gdje:
represents hydrogen or R1 and R2, together with the carbon atoms marked 'a' and 'b' form a cyclohexyl ring, 
predstavlja vodik ili R1 i R2, zajedno s atomima ugljika označenima s ’a’ i ’b’, tvore cikloheksilni prsten,
and R3 independently represent hydrogen or an alkyl(C1-3) group, or R2 and R3, together with the carbon atom marked 'b' form a cyclopentyl or cyclohexyl ring, 
i R3 neovisno predstavljaju vodik ili alkil(C1-3) skupinu, ili R2 i R3, zajedno s atomom ugljika označenim s 'b' tvore ciklopentilni ili cikloheksilni prsten,
and R5 independently represent hydrogen, an alkyl(C1-3) group, or R3 and R4, together with the carbon atoms marked 'b' and 'c' form a C3-8-cycloalkyl ring, 
i R5 neovisno predstavljaju vodik, alkil(C1-3) skupinu, ili R3 i R4, zajedno s atomima ugljika označenima s ’b’ i ’c’, tvore C3-8-cikloalkilni prsten,
and R7 independently represent a hydrogen atom, or an alkyl(C1-3) group, or an alkyl(C1-4) group substituted with one or more halogen atoms, or a methoxy group, or a cyclohexyl group, or a 4-piperidinyl group, 
i R7 neovisno predstavljaju atom vodika, ili alkil(C1-3)skupinu, ili alkil(C1-3) skupinu supstituiranu s jednim ili više halogen atoma, ili metoksi skupinu, ili cikloheksilnu skupinu, ili 4-piperidinil skupinu,
A compound as claimed in claim 1 of formula (1), or a tautomer, stereoisomer, N-oxide, or a pharmacologically acceptable salt, hydrate or solvate of any of the foregoing, wherein: R1, R4, R5 and R6 represents hydrogen, R2 and R3 independently represent an alkyl(C1-3) group, or R2 and R3, together with the carbon atom marked 'b' form a cyclopentyl, or cyclohexyl ring, R7 represents an alkyl(C1-3) group and R8 has the meanings as given in claim 1. 
Spoj prema zahtjevu 1 formule (1) ili tautomer, stereoizomer, N-oksid, ili farmakološki prihvatljiv(a) sol, hidrat ili solvat od bilo kojeg od navedenih, naznačen time, da:, R4, R5i R6predstavljaju vodik, R2i R3neovisno predstavljaju alkil(C1-3) skupinu, ili R2 i R3, zajedno s atomom ugljika označenim s ’b', tvore ciklopentilni ili cikloheksilni prsten, R7 predstavlja alkil(C1-3) skupinu, a R8 ima značenje navedeno u zahtjevu 1.
The medicament of claim 6, for use in the treatment of Parkinson's disease, Huntington's chorea, schizo-phrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes. 
Lijek prema zahtjevu 6, naznačen time, da se upotrebljava za liječenje Parkinson-ove bolesti, Huntington-ove horeje, shizofrenije, anksioznosti, depresije, manične depresije, psihoze, epilepsije, opsesivnih kompulzivnih poremećaja, poremećaja raspoloženja, migrene, Alzheimer-ove bolesti, kognitivnog propadanja zbog starosti, blagog kognitivnog oštećenja, poremećaja spavanja, poremećaja jedenja, anoreksije, bulimije, poremećaja jedenja nakon pijanke, napada panike, akatizije, poremećaja hiperaktivnosti s pomanjkanjem pažnje, poremećaja pomanjkanja pažnje, simptoma ustezanja od uzimanja kokaina, etanola, nikotina ili benzodiazepina, bolova, poremećaja povezanih s ozljedama kralježnice ili ozljedama glave, hidrocefalusa, funkcionalnog poremećaja crijeva, sindroma osjetljivih crijeva, pretilosti i dijabetesa tipa-2.
The medicament of claim 6, further comprising: at least one additional therapeutic agent. 
Lijek prema zahtjevu 6, naznačen time, da nadalje obuhvaća barem jedno dodatno terapeutsko sredstvo.
Combination preparation comprising (i) a compound as claimed in claim 1 of formula (1), or pharmacologically acceptable salts or hydrates thereof, and (ii) an other medicament, for simultaneous, separate or sequential use in the treatment of Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes. 
Kombiniram preparat, naznačen time, da obuhvaća (i) spoj prema zahtjevu 1 formule (1), ili njegove farmakološki prihvatljive soli ili hidrate, i (ii) jedan drugi lijek, za istovremenu, odvojenu ili uzastopnu uporabu u liječenju Parkinson-ove bolesti, Huntington-ove horeje, shizofrenije, anksioznosti, depresije, manične depresije, psihoze, epilepsije, opsesivnih kompulzivnih poremećaja, poremećaja raspoloženja, migrene, Alzheimer-ove bolesti, kognitivnog propadanja zbog starosti, blagog kognitivnog oštećenja, poremećaja spavanja, poremećaja jedenja, anoreksije, bulimije, poremećaja jedenja nakon pijanke, napada panike, akatizije, poremećaja hiperaktivnosti s pomanjkanjem pažnje, poremećaja pomanjkanja pažnje, simptoma ustezanja od uzimanja kokaina, etanola, nikotina ili benzodiazepina, bolova, poremećaja povezanih s ozljedama kralježnice ili ozljedama glave, hidrocefalusa, funkcionalnog poremećaja crijeva, sindroma osjetljivih crijeva, pretilosti i dijabetesa tipa-2.
Compounds of the general formula (1z): wherein the symbols have the meanings as given in claim 1, and tautomers, stereoisomers and N-oxides thereof, such compounds being useful in the synthesis of compounds of the general formula (1), with the proviso that when R1, R2, R3, R5 and R6 are hydrogen, and R4 is phenyl, R7 can not be hydrogen or 4,6-dimethylpyrimidin-2-yl; and with the proviso that when R2, R3, R5, R6 and R7 are hydrogen, and R1 is methyl, R4 can not be phenyl, 2-hydroxyphenyl or 4-methylphenyl. 
Spojevi, naznačeni time, da imaju opću formulu (1Z): [image] gdje simboli imaju značenja navedena u zahtjevu 1, i njihovi tautomeri, stereoizomeri i N-oksidi, a takvi spojevi su korisni u sintezi spojeva opće formule (1), uz uvjet da kada R1, R2, R3, R5i R6su vodik, i R4je fenil, R7ne može biti vodik ili 4,6-dimetilpirimidin-2-il; te uz uvjet da kada R2, R3, R5, R6 i R7 su vodik, i R1 je metil, R4 ne može biti fenil, 2-hidroksifenil ili 4-metilfenil.
reacting a compound of formula (X), obtainable by reacting a compound of formula (IX) with an alkyl halide, for instance methyliodide, with a pyrazoline in the presence of a base, to yield a compound of formula (1z), 
reakcija spoja formule (X), koji se dobiva reakcijom spoja formule (IX) s alkil halidom, na primjer metil-jodidom, s pirazolinom u prisutnosti baze, za postizanje spoja formule (1z),
reacting a compound of formula (1z) with a sulfonyl halide of formula R8-SO2-X, wherein X is Br, Cl or F, in an aprotic solvent such as dichloromethane, in the presence of a base such as diisopropylethyl-amine, 
reakcija spoja formule (1z) sa sulfonil halidom formule R8-SO2-X, gdje X je Br, Cl ili F, u aprotičnom otapalu kao što je diklorometan, u prisutnosti baze kao što je diizopropiletil-amin, [image]
Use of a compound as claimed in any of the claims 1-5 for the preparation of a pharmaceutical composition for the treatment or prophylaxis of Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes. 
Uporaba spoja prema bilo kojem zahtjevu 1 do 5, naznačena time, da je za proizvodnju farmaceutskog sastava za liječenje ili profilaksu Parkinson-ove bolesti, Huntington-ove horeje, shizofrenije, anksioznosti, depresije, manične depresije, psihoze, epilepsije, opsesivnih kompulzivnih poremećaja, poremećaja raspoloženja, migrene, Alzheimer-ove bolesti, kognitivnog propadanja zbog starosti, blagog kognitivnog oštećenja, poremećaja spavanja, poremećaja jedenja, anoreksije, bulimije, poremećaja jedenja nakon pijanke, napada panike, akatizije, poremećaja hiperaktivnosti s pomanjkanjem pažnje, poremećaja pomanjkanja pažnje, simptoma ustezanja od uzimanja kokaina, etanola, nikotina iii benzodiazepina, bolova, poremećaja povezanih s ozljedama kralježnice ili ozljedama glave, hidrocefalusa, funkcionalnog poremećaja crijeva, sindroma osjetljivih crijeva, pretilosti i dijabetesa tipa-2.
A use of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of a disease selected from depression, anxiety, abuse or chronic pain, wherein said medicament is for use in a patient who has previously received another medication for the treatment of said disease which medication was ceased or reduced due to sleep or sexually related adverse events. 
Uporaba 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina i njegovih farmaceutski prihvatljivih soli u proizvodnji lijeka za liječenje bolesti izabrane između depresije, anksioznosti, ovisnosti ili kronične boli, pri čemu je taj lijek namijenjen uporabi kod bolesnika koji je prethodno liječen drugim lijekom za tu bolest, a čija je primjena prestala ili je smanjena zbog nuspojave povezane s poremećajem spavanja ili seksualnosti.
1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof for use in the treatment of a disease selected from depression, anxiety, abuse or chronic pain in a patient who has previously received another medication for the treatment of said disease which medication was ceased or reduced due to sleep or sexually related adverse events. 
-[2-(2,4-dimetilfenilsulfanil)fenil]piperazin i njegove farmaceutski prihvatljive soli za uporabu u liječenju bolesti izabrane između depresije, anksioznosti, ovisnosti ili kronične boli, kod bolesnika koji je prethodno liječen drugim lijekom za tu bolest, a čija je primjena prestala ili je smanjena zbog nuspojave povezane s poremećajem spavanja ili seksualnosti.
A compound having the general formula I wherein Z represents a group of the formula -C≡C-R2 or -CH=H-R2; 
Spoj koji ima opću formulu I [image] gdje Z predstavlja skupinu formule -C≡C-R2 ili -CH=CH-R2;
with the proviso that if Z represents a group of the formula -CH=CH-R2 then R1 represents a hydrogen atom and oxo and hydroxy are excluded from the optional substituents; or an enantiomer, diastereomer, N-oxide or pharmaceutically acceptable salt thereof. 
uz uvjet da ukoliko Z predstavlja skupinu formule –CH=CH-R2, tada R1 predstavlja atom vodika, a okso i hidroksi su isključeni iz mogućih supstituenata, ili njegov enantiomer, diasteroizomer, N-oksid ili farmaceutski prihvatljiva sol.
A compound according to claim 6 in which R2 represents an optionally substituted pyrrolidinyl, thiazolyl, pyridyl, quinolyl, quinoxalinyl or phenyl group, the substituents for each optionally substituted group being a fluorine, chlorine or bromine atom or an oxo, nitro, cyano, cyanomethyl, acetyl, methyl, methoxy, ethoxy, isopropoxy, trifluoromethyl, trifluoromethoxy, acetamino, 2,2-dimethylpropanoylamino, 3,3-dimethyl-2-oxo-1-azetidinyl, 1-pyrrolidinylmethyl, 1H-pyrazol-1-yl, 3-methyl-1,2,4-oxadiazol-5-yl or morpholino group. 
Spoj prema zahtjevu 6, u kojem R2 predstavlja opcijski supstituirani pirolidinil, tiazolil, piridil, kinolil, kinoksalinil ili fenil skupinu, a supstituenti za svaku opcijski supstituiranu skupinu su atom fluora, klora ili broma, okso, nitro, cijano, cijanometil, acetil, metil, metoksi, etoksi, izopropil, trifluorometil, trifluorometoksi, acetamino, 2,2-dimetilpropanoilamino, 3,3-dimetil-2-okso-1-azetidinil, 1-pirolidinilmetil, 1H-pirazol-1-il, 3-metil-1,2,4-oksadiazol-5-il ili morfolino skupina.
Any one of the following compounds according to claim 1, or an enantiomer, diastereomer, N-oxide or pharmaceutically acceptable salt thereof, namely: 
Bilo koji od slijedećih spojeva prema zahtjevu 1, ili njihov enantiomer, diasteroizomer, N-oksid ili farmaceutski prihvatljiva sol, naime:
Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine for use according to any one of claims 1-3, wherein it is for use in a method of treating schizophrenifonn disorder and schizoaffective disorders. 
Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je za uporabu u postupku liječenja shizofreniformnog i shizoafektivnih poremećaja.
A composition comprising (A) a therapeutically effective amount of tegafur, (B) a dihydropyrimidine dehydrogenase inhibitor in an amount effective for potentiating the antitumor effect and (C) oxonic acid or a pharmaceutically acceptable salt thereof in an amount effective for suppressing gastrointestinal toxicity for use in the treatment of a patient suffering from cancer susceptible of being treated with 5-FU, wherein the treatment is carried out under fasting conditions that occur at least one hour before a meal, wherein the above components are simultaneously administered, wherein 0.1 to 5 mol of a dihydropyrimidine dehydrogenase inhibitor and 0.1 to 5 mol of oxonic acid or a pharmaceutically acceptable salt thereof per 1 mol of tegafur are administered and wherein the antitumor effect of tegafur is potentiated while reducing gastrointestinal toxicity in the patient in need of such treatment. 
Sastav, naznačen time, da sadrži (A) terapeutski učinkovitu količinu tegafura, (B) inhibitor dehidrogenaze dihidropirimidina u količini učinkovitoj za potenciranje protutumorskog učinka i (C) oksoničku kiselinu ili njenu farmaceutski prihvatljivu sol u količini učinkovitoj za sprečavanje gastrointestinalne toksičnosti, te time da je za uporabu u liječenju pacijenta koji pati od raka osjetljivog na liječenje sa 5-FU, pri čemu se liječenje provodi u stanju gladi koje nastupa najmanje jedan sat prije jela, kada se gore navedeni sastojci daju istovremeno, dok se daje 0,1 do 5 mola inhibitora dehidrogenaze dihidropirimidina i 0,1 do 5 mola oksoničke kiseline ili njene farmaceutski prihvatljive soli po 1 molu tegafura, pri čemu se protutumorski učinak tegafura potencira dok se smanjuje gastrointestinalna toksičnost kod pacijenta kojem je potrebno takvo liječenje.
Composition for use according to claim 24, wherein the dihydropyrimidine dehydrogenase inhibitor is 2,4-dihydroxy-5-chloropyridine. 
Sastav za uporabu prema zahtjevu 24, naznačen time, da inhibitor dehidrogenaze dihidropirimidina je 2,4-dihidroksi-5-kloropiridin.
Composition for use according to claim 1, wherein the two administrations of the composition are separated by 6 - 12 hours. 
Sastav za uporabu prema zahtjevu 1, naznačen time, da vrijeme između dvije odvojene primjene sastava je od 6 do 12 sati.
Composition for use according to claim 3, wherein the 2,4-dihydroxy-5-chloropyridine (B) and the oxonic acid or a pharmaceutically acceptable salt thereof (C) are used in a molar ratio of (B): (C) = 0.4: 1. 
Sastav za uporabu prema zahtjevu 3, naznačen time, da se 2,4-dihidroksi-5-kloropiridin (B) i oksonička kiselina ili njena farmaceutski prihvatljiva sol (C) koriste u molarnom omjeru od (B): (C) = 0,4: 1.
Composition for use according to claim 1, wherein the pharmaceutically acceptable salt is potassium oxonate. 
Sastav za uporabu prema zahtjevu 1, naznačen time, da farmaceutski prihvatljiva sol je kalijev oksonat.
Composition for use according to claim 3, wherein the tegafur, the 2,4-dihydroxy-5-chloropyridine and the oxonic acid or a pharmaceutically acceptable salt thereof are used in a molar ratio of (tegafur):(2,4-dihydroxy-5-chloropyridine):(oxonic acid or a pharmaceutically acceptable salt thereof) = 1: 0.4: 1. 
Sastav za uporabu prema zahtjevu 3, naznačen time, da se 2,4-dihidroksi-5-kloropiridin i oksonička kiselina ili njena farmaceutski prihvatljiva sol koriste u molarnom omjeru (tegafur): (2,4-dihidroksi-5-kloropiridin): (oksonička kiselina ili njena farmaceutski prihvatljiva sol) = 1: 0,4: 1.
Composition for use according to claim 12, wherein the tegafur is administered at a dose of between 20 mg/m2 to 45 mg/m2 twice daily. 
Sastav za uporabu prema zahtjevu 12, naznačen time, da se tegafur daje u dozi od 20 mg/m2 do 45 mg/m2 dva puta dnevno.
Composition for use according to claim 1, wherein a chemotherapy agent selected from the group consisting of cisplatin, 1,3-bis(2-chloroethyl)-1-nitrosourea, docetaxel, doxorubicin, epirubicin, etoposide, methotrexate, mitomycin, gemcitabine, carboplatin, gefitinib, pemetrexed, Avastin, Cetuximab and paclitaxel is further administered. 
Sastav za uporabu prema zahtjevu 1, naznačen time, da se nadalje primjenjuje kemoterapeutsko sredstvo odabrano iz skupine koju čine cisplatin, 1,3-bis(2-kloroetil)-1-nitrosourea, docetaksel, doksorubicin, epirubicin, etopozid, metotreksat, mitomicin, gemcitabin, karboplatin, gefitinib, pemetreksed, avastin, cetuksimab i paklitaksel.
Composition for use according to claim 9, wherein the chemotherapy agent is cisplatin administered intravenously. 
Sastav za uporabu prema zahtjevu 9, naznačen time, da je kemoterapeutsko sredstvo cisplatin, a primjenjuje se intravenozno.
A composition comprising a therapeutically effective amount of tegafur, 2,4-dihydroxy-5-chloropyridine in an amount effective for potentiating the antitumor effect of tegafur and oxonic acid or a pharmaceutically acceptable salt thereof in an amount effective for suppressing gastrointestinal toxicity for use in the treatment of a mammal suffering from cancer susceptible of being treated with 5-FU, wherein the treatment is carried out under fasting conditions that occur at least one hour before a meal, wherein the above components are simultaneously administered and wherein 0.1 to 5 mol of 2,4-dihydroxy-5-chloropyridine and 0.1 to 5 mol of oxonic acid or a pharmaceutically acceptable salt thereof per 1 mol of tegafur are administered. 
Sastav, naznačen time, da sadrži terapeutski učinkovitu količinu tegafura, 2,4-dihidroksi-5-kloropiridina u količini učinkovitoj za potenciranje protutumorskog učinka tegafura te oksoničku kiselinu ili njenu farmaceutski prihvatljivu sol u količini učinkovitoj za sprečavanje gastrointestinalne toksičnosti, te koji je za uporabu u liječenju sisavaca koji pate od raka osjetljivog na liječenje sa 5-FU, pri čemu se liječenje provodi u stanju gladi koje nastupa najmanje jedan sat prije jela, kada se gore navedeni sastojci daju istovremeno, dok se daje 0,1 do 5 mola 2,4-dihidroksi-5-kloropiridina i 0,1 do 5 mola oksoničke kiseline ili njene farmaceutski prihvatljive soli po 1 molu tegafura.
Composition for use according to claim 12, wherein the administrations are twice over the course of a day, under fasting conditions. 
Sastav za uporabu prema zahtjevu 12, naznačen time, da je davanje sastava dva puta u toku dana, u stanju gladi.